Elsilimomab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 457123854

| type = mab

| mab_type = mab

| source = o

| target = IL-6

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|correct|CAS}}

| CAS_number = 468715-71-1

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = DGK38A42AE

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| chemical_formula =

| molecular_weight =

}}

Elsilimomab (also known as B-E8) is a mouse monoclonal antibody.{{cite web |url=http://whqlibdoc.who.int/druginfo/INN_2004_list51.pdf |archive-url=https://web.archive.org/web/20091016222527/http://whqlibdoc.who.int/druginfo/INN_2004_list51.pdf |url-status=dead |archive-date=October 16, 2009 |title=WHO Drug Information |quote=p11:immunoglobulin G1, anti-(human interleukin 6) (mouse monoclonal B-E8 heavy chain), disulfide with mouse monoclonal B-E8 k-chain, dimer }} B-E8 was developed by Diaclone,{{cite web |url=https://www.diaclone.com/product/855.050.000-anti-human-il-6-azide-free/347 |title=Datasheet B-E8 mAb | work = Diaclone }} a French company which produces many mouse monoclonal antibodies.

It (OPR-003) targets (and blocks) Interleukin-6.{{cite news |url=http://www.genengnews.com/gen-news-highlights/first-fully-human-anti-il6-antibody-under-development/6779735/ |title=First Fully Human Anti-IL6 Antibody Under Development | work = Genetic Engineering & Biotechnology News |date=Oct 2006 }}

It has undergone a number of early stage clinical trials, e.g. for lymphoma and myeloma.{{cite journal | vauthors = Fulciniti M, Hideshima T, Vermot-Desroches C, Pozzi S, Nanjappa P, Shen Z, Patel N, Smith ES, Wang W, Prabhala R, Tai YT, Tassone P, Anderson KC, Munshi NC | display-authors = 6 | title = A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma | journal = Clinical Cancer Research | volume = 15 | issue = 23 | pages = 7144–52 | date = December 2009 | pmid = 19934301 | pmc = 2787636 | doi = 10.1158/1078-0432.CCR-09-1483 }}

It was used as a template to develop a high-affinity, antagonist, fully human anti-IL-6 mAb 1339.